Japan Herceptin Market Size, Share, and COVID-19 Impact Analysis, By Product (Biosimilar and Biologic), By Application (Breast Cancer and Stomach/Gastric Cancer), and Japan Herceptin Market Insights, Industry Trend, Forecasts to 2035

Japan Herceptin Market Insights Forecasts to 2035

• The Japan Herceptin Market Size Was Estimated at USD 167.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.23% from 2025 to 2035
• The Japan Herceptin Market Size is Expected to Reach USD 360.0 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan Herceptin Market Size is anticipated to Reach USD 360.0 Million by 2035, Growing at a CAGR of 7.23% from 2025 to 2035. The Japanese herceptin market is driven by various factors, including rising prevalence of HER2-positive breast cancer, rising awareness about targeted cancer therapies, aging population, and improved diagnostics.

Market Overview

Herceptin, also known as trastuzumab, is a monoclonal antibody used in the treatment of HER2-positive breast cancer and gastric cancer. It works by acting against the overexpressed HER2 protein in certain cancer cells and suppressing it from causing tumor growth. They are available in biosimilar and biologic types. One of the major drivers propelling the herceptin market is the rising prevalence of HER2-positive breast cancer, which creates the demand for effective therapies like herceptin. The rising adoption of biosimilars is making HER2-targeted treatments more affordable and accessible, has boosted patient uptake, and is contributing to the overall market expansion. The growing popularity of personalized medicines is a key trend in this market. This trend offers a potential opportunity for the development of treatments based on an individual's genetic profile.

Report Coverage

This research report categorizes the market for the Japan Herceptin market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan Herceptin market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan Herceptin market.

Driving Factors

The Japan herceptin market is primarily driven by rising cases of HER2-positive breast cancer and gastric cancer, especially among the aging population, which creates the demand for targeted therapies. The rising adoption of biosimilars plays an important role in the expansion of the market, as biosimilars are cost-effective. The rising awareness about cancer and early detection further boosts the market growth. Additionally, technological advancements positively contribute to the market growth.

Restraining Factors

One of the notable restraints is that the high cost of treatment creates financial pressure on patients as well as the healthcare system. Additionally, the competition from alternative biosimilars further limits the market expansion.

Market Segmentation

The Japan Herceptin market share is classified into product and application.

• The biosimilar segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan Herceptin market is segmented by product into biosimilar and biologic. Among these, the biosimilar segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to rising demand for cost-effective oncology therapies and growing acceptance of biosimilars by clinicians and payers.

• The breast cancer segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.

The Japan Herceptin market is segmented by application into breast cancer and stomach/gastric cancer. Among these, the breast cancer segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to the high prevalence of HER2-positive breast cancer. Additionally, early screening and diagnosis contributed to the segmental growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan herceptin market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Roche Holding AG
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Nippon Kayaku
• Daiichi Sankyo
• Chugai Pharmaceutical
• Other

Recent Developments

• In November 2021, Chugai Pharmaceutical received MHLW approval for Herceptin (trastuzumab) to treat advanced or recurrent HER2-positive salivary gland cancer.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan Herceptin market based on the below-mentioned segments:

Japan Herceptin Market, By Product

• Biosimilar
• Biologic

Japan Herceptin Market, By Application

• Breast Cancer
• Stomach/Gastric Cancer